Journal article

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]

Stephen John Clarke, Matthew Burge, Kynan Feeney, Peter Gibbs, Kristian Jones, Gavin Marx, Mark P Molloy, Timothy Price, William HH Reece, Eva Segelov, Niall C Tebbutt



BACKGROUND: In spite of demonstrating prognostic and possibly predictive benefit in retrospective cohorts and meta-analyses of cancer populations, including colorectal cancer (CRC), prospective evaluation of the relationship between neutrophil to lymphocyte ratio (NLR) and treatment outcomes in previously untreated mCRC patients receiving bevacizumab-based therapy has not yet been performed. METHODS: An open-label, single arm, multi-centre study. Patients received first-line bevacizumab plus XELOX or mFOLFOX6 (Phase-A) and continued bevacizumab plus FOLFIRI beyond first progression (Phase-B). Analyses included the association of NLR with phase A progression free survival (PFS) and overall su..

View full abstract


Funding Acknowledgements

The study was sponsored by Roche Products, Pty. Limited. The funder provided support in the form of salaries for authors KJ as an employee of the funder and WR as an employee of the Clinical Research Organization contracted to perform the data management and statistical analyses of the study. The funder was involved in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.